Loading data
CGNTNasdaq
| Unit: USD | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 400.04 m USD | 350.63 m USD | 313.4 m USD | 312.06 m USD | 474.04 m USD |
| Cost of revenue | 110.34 m USD | 103.71 m USD | 98 m USD | 119.94 m USD | 132.4 m USD |
| Gross profit | 289.7 m USD | 246.92 m USD | 215.4 m USD | 192.13 m USD | 341.64 m USD |
| Research and development expense | 122.34 m USD | 108.27 m USD | 107.28 m USD | 140.32 m USD | 143.36 m USD |
| Selling, general and administrative expense | 153.65 m USD | 143.52 m USD | 125.78 m USD | 154.35 m USD | 185.87 m USD |
| Operating profit | 13.26 m USD | -5.13 m USD | -18.05 m USD | -103.32 m USD | 10.96 m USD |
| Interest expense | — | — | 16 k USD | 1.6 m USD | 196 k USD |
| Profit before tax | 11.34 m USD | -4.37 m USD | -13.26 m USD | -97 m USD | 8.26 m USD |
| Income tax expense | 6.73 m USD | 2.86 m USD | -1.61 m USD | 12.96 m USD | 18.52 m USD |
| Net income (reported basis) | -638 k USD | -12.05 m USD | -15.57 m USD | -114.13 m USD | -14.89 m USD |
| Basic earnings per share | -0.01 USD/share | -0.17 USD/share | -0.22 USD/share | -1.68 USD/share | -0.22 USD/share |
| Diluted earnings per share | -0.01 USD/share | -0.17 USD/share | -0.22 USD/share | -1.68 USD/share | -0.22 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.